ArticleScientific reports2025
SLC10A3 regulates ferroptosis of glioblastoma through the STAT3/GPX4 pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Serotonergic SLC10A4 regulates extracellular serotonin levels and antidepressant responsiveness.Molecular psychiatry · 2026Article
- Solute carrier membrane transporters: emerging targets in CNS disorders.Nature reviews. Drug discovery · 2026Review
- The role of STAT3 in regulating ferroptosis in cancer: molecular mechanisms and targeted therapeutic perspectives.Cancer gene therapy · 2026Review
- Review
- Comprehensive analysis of the potential role of Ferroptosis-related genes in glioblastoma multiforme.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Ferroptosis in Glioblastoma and Neuroblastoma: Molecular Mechanisms and Novel Therapeutic Strategies.Current issues in molecular biology · 2026Review
- Glioblastoma pathophysiology: roles of aging driven changes in STAT3 interactions with NF-κB dimer components in the modulation of the mitochondrial melatonergic pathway and night-time inflammation resolution.Exploration of targeted anti-tumor therapy · 2026Review
- Ferroptosis and metabolic reprogramming in the immunosuppressive microenvironment of glioblastoma: emerging mechanisms and novel strategies.Frontiers in immunology · 2026Review
- SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration.Frontiers in oncology · 2026Article
- ZBTB20 promotes ferroptosis through inhibiting TMEM109 expression in glioblastoma cells.International journal of oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ferroptosis is closely related to disease progression and treatment response in human brain gliomas; however, the regulatory mechanisms involved remain to be elucidated. Identifying new ferroptosis regulatory factors holds promise for addressing the aberrant regulation of ferroptosis in glioblastoma (GBM) and overcoming its treatment resistance. In this research, bioinformatics revealed that SLC10A3 is upregulated in GBM and correlates with poor patient prognosis. Functional analysis showed that SLC10A3 regulates GBM growth and progression through ferroptosis and that silencing SLC10A3 enhances sensitivity to the ferroptosis inducer Erastin. Mechanistically, SLC10A3 modulates STAT3 transcription and phosphorylation, impacting GBM ferroptosis via the STAT3-GPX4 pathway, and the STAT3 phosphorylation inhibitor Stattic effectively reverses this process. In vivo experiments also demonstrated that silencing SLC10A3 effectively induces ferroptosis in GBM and inhibits GBM progression. Our findings may help elucidate the mechanisms behind GBM resistance and offer new potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.